Two complementary pipeline products added through a licensing agreement with France-based pharmaceutical company Laboratoire Aguettant
Pre-filled, ready-to-use syringes of commonly used products for acute care
Pre-filled, ready-to-use ephedrine and phenylephrine syringes combined market opportunity is estimated at over $100 million
Minimal expected cost to get the products through NDA submissions and potential approval
NDA submission for ephedrine expected in 2023 and phenylephrine expected in 2024
Approved and marketed products in Europe and other regions outside the U.S.